

## New SITC Webinar Available

# Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer & the International Bladder Cancer Group

Discuss the publication in-depth with experts, ask questions and explore topics such as: non-muscle and muscle invasive bladder cancer, metastatic unresectable and locally advanced disease. This session will be available free-of-charge and held live to allow questions with the authors.



Join the webinar on March 18, 2024, from 4–5 P.M. CST

## Webinar Learning Objectives

1. Understand appropriate definitions and end points that are relevant to the understanding of existing trials in each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer (NMIBC) to metastatic disease.
2. Understand nuances of rationally selected endpoints, eligibility criteria, response measurement, statistical analyses (including minimal value for effect and sample size considerations), and pathology considerations.
3. Apply these key clinical design elements and standardized criteria to their clinical trials (and practice) to identify optimal treatment options and improve outcomes for patients.
4. Apply these criteria to develop comparable and robust data sets for meta-analyses.

## Moderators

**Matthew D. Galsky, MD**  
Mount Sinai

**Ashish Kamat, MD, MBBS**  
University of Texas MD  
Anderson Cancer Center

## Faculty

**Andrea Apolo MD**  
National Cancer Institute/  
Center for Cancer Research

**Shilpa Gupta, MD**  
Cleveland Clinic Taussig  
Cancer Institute

**Seth Lerner, MD, FACS**  
Baylor College of Medicine

**Sarah P. Psutka**  
University of Washington

On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the **“Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group,”** in the **Journal of Clinical Oncology**.

These recommendations provide a detailed clinical trial design guide to maximize the chance of capturing the benefit of medical therapies for each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer (NMIBC) to metastatic disease.

## Key Bladder Cancer Stage-Specific Recommendations

- Rationally selected endpoints
- Eligibility criteria
- Response measurement
- Statistical analyses (including minimal value for effect and sample size considerations)
- Pathology considerations